

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/13, 9/107	A1	(11) International Publication Number: WO 97/36611 (43) International Publication Date: 9 October 1997 (09.10.97)
(21) International Application Number: PCT/US97/04794 (22) International Filing Date: 26 March 1997 (26.03.97) (30) Priority Data: 08/627,187 3 April 1996 (03.04.96) US (71) Applicant: RESEARCH TRIANGLE PHARMACEUTICALS LTD. [US/US]; 4364 South Alston Avenue, Durham, NC 27713-2280 (US). (72) Inventors: PARIKH, Indu; 2558 Booker Creek Road, Chapel Hill, NC 27713 (US). MISHRA, Awadhesh; 4364 S. Alston Avenue, Durham, NC 27713 (US). (74) Agent: CRAWFORD, Arthur, R.; Nixon & Vanderhye P.C., 8th floor, 1100 North Glebe Road, Arlington, VA 22201-4714 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CYCLOSPORIN EMULSIONS (57) Abstract This invention comprises pharmaceutical compositions consisting essentially of an oil-in-water emulsion containing a synthetic medium chain triglyceride in which is dissolved a therapeutically effective amount of a cyclosporin, phospholipid and optionally free fatty acid or a salt thereof, non-ionic surfactant, ionic surfactant, glycerol, salts, buffers, preservative, osmotic modifier and antioxidant.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan ¹		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CYCLOSPORIN EMULSIONS

1

This invention relates to pharmaceutical compositions containing a cyclosporin in an oil-in-water emulsion and in particular features the use of medium chain length triglycerides and free fatty acids to enhance the solubility of the cyclosporin in the oil phase to form stable and heat sterilizable oil-in-water emulsions without the need
5 of potential toxic additives for the lipophilic carrier.

BACKGROUND OF INVENTION

Cyclosporins, a group of nonpolar cyclic oligopeptides with immunosuppressant
10 activity, are known to be very poorly soluble in water and are thus difficult to formulate into injectable preparations containing an acceptable quantity of the drug. Due to their poor solubility, cyclosporins have been formulated in various non-aqueous materials including organic solvents such as ethanol and polyoxyethylated castor oils [cremophors] which are potentially toxic.

15

The patent literature describes various formulations and pharmaceutical presentations of lipophilic drugs. U.S. patent 4,073,943 to Wretling describes a carrier system for use in enhancing parenteral administration of a pharmacologically active oil-soluble agent, the carrier system being a stable, oil-in-water emulsion containing a
20 pharmacologically inert lipoid as a hydrophobic phase dispersed in a hydrophilic buffer. The lipoid is dispersed in the emulsion as finely divided particles having a mean diameter of less than 1 micron. The active agent is oil-soluble and is predominantly dissolved in the lipoid. The compositions contain a lipophilic core of a fat of vegetable origin.

25

In the carrier system described the drug must be soluble in the lipoid, although it may have some solubility in the hydrophilic phase. The composition will usually consist of an inert oil or fat dispersed in an aqueous solution. To obtain a stable emulsion, it is necessary to include a stabilizer of natural or synthetic origin, for

example phosphatides, polypropylene glycol, polyethylene glycol or polyglycerol monooleate.

U.S. patent 4,298,594 to Sears describes the controlled release of an active agent
5 contained in a vehicle in the form of microreservoirs in non-vesicular form having
diameters between 250 Å and 1000 Å, or vesicular form having diameters ranging
between about 190 Å and about 300 Å, or both nonvesicular and vesicular forms.
The vehicle is formed of a phospholipid constituent and a phospholipid-immiscible
lipid constituent. Preferred phospholipid-immiscible lipids include triglyceride
10 and/or cholesterol ester; the phospholipid-immiscible lipid must essentially be
immiscible in the phospholipid bilayer. The nonvesicular form is a fat emulsion and
the vesicular form is a liposome.

Cyclosporin-containing pharmaceutical formulations for intravenous administration
15 are described in EPO 0 570829 A1 to Dietl. The emulsions are composed of
cyclosporin microcrystals in an oily carrier composed of medium-chain triglyceride
oil, together optionally with vegetable oil, phospholipid, non-ionic surfactant and
ionic surfactant. The lipophilic core composition is composed of natural oil,
optionally with free or sodium or potassium salt of a fatty acid.

20

In the present invention, the lipophilic core composition includes synthetic or
derivatized triglycerides and optionally free fatty acids or salts thereof, which are
capable of solubilizing more cyclosporin than natural oils and allow the preparation
of emulsions with greater cyclosporin payloads. In the present invention, the
25 cyclosporin is completely dissolved in the lipophilic core.

U.S. patent 4,725,442 to Haynes describes microdroplets from about 100 Angstroms
to one micron in diameter having a sphere of a substantially water-insoluble drug
dissolved in an organic liquid such as an alkane, a dialkyl ester, a long-chain ester,
30 a hydrophobic ester, a biocompatible silicone, a biocompatible high molecular

weight fluorocarbon, oil-soluble vitamin, the liquid and drug surrounded in a layer of phospholipid.

U.S. patent 5,342,625 to Hauer describes cyclosporin-containing pharmaceutical compositions in the form of a microemulsion preconcentrate having a hydrophilic phase component of a pharmaceutically acceptable di-or partial-ether or 1,2-propylene glycol; a lipophilic phase component, for instance an organic solvent such as ethanol, and a surfactant; when diluted 1:1 with water an oil-in-water microemulsion having average particle size of less than about 1,000Å is formed. These microemulsions do not contain a triglyceride core and are distinctly different from emulsions since they form spontaneously (do not require addition of energy).

U.S. patent 4,990,337 to Kurihara et al describes emulsions containing cyclosporin and a mixture of medium chain mono- or di-glycerides. The use of medium chain triglycerides and mono- and di-glycerides to solubilize cyclosporin A is discussed. Kurihara concludes that the use of triglycerides, even medium chain triglycerides, is not acceptable due to poor solubility of cyclosporine. The patentees report that cyclosporins have excellent solubility in the mono- and di-glycerides of intermediate molecular weight fatty acids, which are easily emulsified in water, and which can thus substantially improve the dispersibility of cyclosporin in water and aqueous media. However, it is generally known that mono- and di-glycerides have detergent properties which enhance irritation and damage to tissues.

It is an object of this invention to provide a pharmaceutically acceptable cyclosporin preparation with a high drug payload.

It is a further object of this invention to provide a pharmaceutically acceptable cyclosporin preparation without potentially toxic organic solvents such as ethanol and cremophors.

4

It is another object of this invention to provide a pharmaceutically acceptable cyclosporin preparation which can be used parenterally.

It is an additional object of this invention to provide a pharmaceutically acceptable
5 cyclosporin preparation which can be heat sterilized.

It is a further object of this invention to provide a method of forming such a preparation.

10

SUMMARY OF THE INVENTION

This invention comprises pharmaceutical compositions consisting essentially of an oil-in-water emulsion containing a synthetic medium chain triglyceride in which is
5 dissolved a therapeutically effective amount of a cyclosporin, phospholipid and optionally free fatty acid or a salt thereof, non-ionic surfactant, ionic surfactant, glycerol, salts, buffers, preservative, osmotic modifier and antioxidant.

The invention provides stable emulsions consisting of non-toxic excipients, which
10 allow for delivery of high concentrations of cyclosporin (up to ~7.5% w/w cyclosporin A). We have found that medium chain triglycerides, as herein defined, have the ability to solubilize cyclosporin (~150-200 mg cyclosporin A/mL oil) and form stable emulsions without the need of potentially toxic additives such as ethanol, propylene glycol, cremophors and the like. Using lipids as stabilizers, the inventive
15 emulsions of the present invention retain size stability during heat sterilization, storage, and under the stress conditions of shaking, vibrating and thermal cycling between 4 and 40°C.

Further entailed in this inventions is the addition of a free fatty acid or salt thereof
20 to the medium chain triglycerides to further enhance the cyclosporin solubility (~300-450 mg cyclosporin A/mL oil).

Particularly preferred pharmaceutical compositions are essentially oil-in-water emulsions composed of about 10% to about 40% of a synthetic medium chain
25 triglyceride containing C₈-C₁₂ fatty acid chains. about 1% to about 10% w/w of a cyclosporin dissolved in the triglyceride; about 1 to about 5% w/w of a natural or synthetic phospholipid, about 0.1 to about 10% w/w unsaturated free fatty acids or salts thereof to enhance the solubility of the cyclosporin; with the balance an aqueous phase optionally also including glycerol, salts, buffers, surfactants, antioxidants or
30 preservatives.

Preferably the synthetic medium chain triglyceride has C₈-C₁₀ fatty acid chains, particularly the synthetic medium chain triglyceride contains C₈ fatty acid chains.

The invention also includes a method of preparing a stable emulsion of cyclosporin including the steps of: dissolving cyclosporin in a synthetic medium chain triglyceride to which has been added a cyclosporin solubility enhancing amount of an unsaturated free fatty acid or a salt thereof and phospholipid, to produce an oil phase; preparing an aqueous phase containing water, glycerol and also optionally an ionic or non-ionic surfactant; mixing the oil phase with the aqueous phase and
10 subjecting the mixture to homogenizing conditions to prepare a stable cyclosporin emulsion in which substantially all of the particles have a size less than 1 µm; and heat sterilizing the emulsion.

DETAILED DESCRIPTION OF THE INVENTION

15 The cyclosporins are a class of pharmacologically active substances known primarily for their immunosuppressant activity primarily in organ transplants. Cyclosporin A, isolated as an amorphous powder from fungal sources by chromatography, is the most common form, however cyclosporins B through I have been identified and various synthetic analogues have been prepared. Preferred are
20 cyclosporins A, B, D and G (*The Merck Index*, 11th Edition, 2759). The formulations of the present invention may contain about 0.1 to about 10% w/w, preferably at least 1%, and ideally between about 2.5 and about 7.5% cyclosporin.

The lipid component may be any natural or synthetic phospholipid, for example
25 phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, lysophospholipids, egg or soybean phospholipid or a combination thereof. The phospholipid may be salted or desalted. The lipid component may also include cholesterol, sphingomyelin or combinations of any of the above-mentioned lipid components. The lipid

component will normally represent between about 1 to about 10% w/w, preferably between about 1 to about 5% w/w.

The aqueous phase is primarily water plus glycerol, salts, buffers, osmotic modifiers, and the like. Nonionic or ionic surfactants, antioxidants and preservatives may be present.

The synthetic medium chain triglycerides employed in the compositions of the invention are characterized as having C₈-C₁₂ fatty acid chains, preferably C₈-C₁₀ fatty acid chains desirably predominantly C₈ fatty acid chain, or other derivatized (synthetic) triglycerides such as MIGLYOL 810, MIGLYOL 818 and MIGLYOL 812 (Hüls, Piscataway, NJ) or LABRAFIL M 1944cs (Gattefossé, Westwood, NJ). The triglyceride may be a mixture of natural and synthetic triglycerides.

Also present may be unsaturated free fatty acids or salts of fatty acids such as linoleic acid (9,12 octadecadienoic acid) and linolenic acid (9,12,15 octadecatrienoic acid) in amounts preferably between 0.1 to about 10% and ideally between 1% to about 5%. The use of these acids, particularly linoleic acid or linolenic acid enhances the solubility of the cyclosporin in the medium chain triglyceride oil.

20

We have determined the solubility of cyclosporin A in a variety of natural oils and synthetic triglycerides. The results indicate that cyclosporin A is more soluble in medium chain triglycerides than long chain triglycerides.

	Natural oil or Synthetic Triglyceride	Solubility (room temp.)
	Coconut Oil (Glycerides, predominantly C12 & C14)	175 mg/mL
	Olive Oil (Glycerides, predominantly C18 & C16)	25 mg/mL
5	Peanut Oil (Glycerides, predominantly C18)	40 mg/mL
	Safflower Oil (Glycerides, predominantly C18)	70-80 mg/mL
	Soybean Oil (Glycerides, predominantly C18 & C16)	36 mg/mL
	Labrafac Lipophile (Triglycerides, mixed C8 & C10)	150 mg/mL
	Miglyoyl 810 (Triglycerides, mixed C8 & C10)	150 mg/mL
10	Miglyol 812 (Triglycerides, mixed C8 & C12)	125 mg/mL
	Miglyoyl 818 (Triglycerides, mixed C8 & C18)	200 mg/mL

The use of synthetic triglycerides, in contrast to the natural oil, greatly increases the payload of cyclosporin. In addition, synthetic sources of triglycerides are chemically
 15 homogeneous, contain fewer and known impurities, and have less batch to batch variation.

We have found that the solubility of cyclosporin is further enhanced by the addition of free fatty acids, such as linoleic and linolenic acid, to the triglycerides. Many
 20 commercially available parenteral emulsions are prepared at or near pH 9 to increase the stability of the emulsion. In contrast to conventional practice, we have found that enhanced cyclosporin solubility in emulsions containing unsaturated free fatty acids such as linoleic acid or linolenic acid is achieved at pHs in the range of about 4.0 to about 7.0. Addition of free fatty acid also improves the stability of the emulsion.

25

In addition, the physical stability of the emulsion may be enhanced by the addition of a non-ionic surfactant or ionic surfactant. These non-ionic surfactants are

pharmaceutically acceptable and do not include solvents such as ethanol or cremophors, which are potentially toxic.

The following table reports the solubility of cyclosporin, in mg/mL at room
5 temperature, in a variety of commercially available synthetic oils and mixed lipids:

Oil	Solubility (room temp)
Labrofac Lipophile	150 mg/mL
Miglyol 810	150 mg/mL
10 Miglyol 812	125 mg/mL
Miglyol 818	200 mg/mL
Miglyol 810/linoleic acid 90:10w/w 66:33 w/w	335 mg/mL 400 mg/mL
15 Miglyol 818/linoleic acid 90:10 w/w 66:33 w/w	425 mg/mL 430 mg/mL
Linoleic acid	> 575 mg/mL

20 While the solubility of cyclosporin in linoleic acid is extremely high, it is too acidic to be used alone in an emulsion formulation. When used in combination with a synthetic medium chain triglyceride it enhances the solubility of the cyclosporin in the oil phase.

25 Miglyol neutral oils [Hüls, Piscataway, N.J.] are esters of medium chain fatty acids. To obtain the medium chain C8-C10 fatty acids, coconut oil is hydrolyzed and the resulting fatty acid mixture is fractionated. The fatty acid mixtures are then

esterified with glycerol or other polyhydric alcohols. Thus, Miglyols are synthetic (sometimes referred to as non-natural) and not natural triglycerides.

	Miglyol Oil	C8 (caprylic)	C10 (capric)
5	Miglyol 810	70-80%	20-30%
	Miglyol 812	50-65%	30-45%
	Miglyol 818	40-60%	25-40%

- 10 Labrofac Lipophile WL1349 [Gattefossé Westwood, N.J.] is a synthetic mixture of medium chain triglycerides (mostly C8 and C10) isolated from coconut oil.

The emulsions of the present invention are prepared as follows: An appropriate amount of cyclosporin is dissolved in the desired oil or mixture of oils at the desired
15 temperature. Also added to this mixture and dispersed are phospholipids. This oil solution is added to an aqueous solution of glycerol, with or without a non-ionic or ionic surfactant, with or without an antioxidant and with or without a preservative. The resulting mixture is then adjusted to the desired pH and homogenized at the desired pressure in batch-wise or continuous cycles until the desired particle size is
20 obtained, typically less than 500 nm volume weighted mean particle size. Several homogenizers are available including Rannie homogenizers (APV) and microfluidizers (Microfluidics Systems). The resulting emulsion can be further pH adjusted and filter- or heat-sterilized.

EXAMPLE 1

A cyclosporin A fatty acid emulsion formulation having the following components

	Components	%w/w
5	Cyclosporin A	5%
	Egg Phospholipid	2.25%
	Dimyristoyl phosphatidylglycerol (DMPG)	0.25%
	Miglyol 810	15%
	Linoleic acid	5%
10	Glycerol	5%
	Water, to make	100 g
	pH	5.5

was prepared by homogenization. The oil phase was prepared by dispersing
15 cyclosporin A in the triglyceride (Miglyol 810) and linoleic acid mixture. Egg
phospholipid and dimyristoylphosphatidylglycerol (DMPG) were added to this
mixture and dispersed in the oil phase and heated to 60-70°C until the components
were dissolved. The oil phase was added to the aqueous phase containing glycerol
and mixed well; the resulting mixture had an initial pH of about 3-4. Sodium
20 hydroxide, aqueous solution, was added to provide a final pH of 5.5. The mixture
was then homogenized and heat sterilized. The particle size ranges of a
representative resulting emulsion were as follows.

Particle Size Ranges: (Measurement error ~ 5-10%)	
Minimum size	20 nm
25% below	175-200 nm
50% below	225-300 nm
75% below	300-375 nm
99% below	600-700 nm
a few tenths of a %	1-2 μ m

10

EXAMPLE 2

In the manner of Example 1, a cyclosporin-containing emulsion with increased levels of linoleic acid and Miglyoyl, to compensate for the higher pH, was prepared having the following components:

15

Components	%w/w
Cyclosporin A	7.5%
Egg phospholipid	1.5%
Miglyol 810	22.5%
Linoleic acid	7.5%
Glycerol	2.5%
Water, to make	100 g
pH	8.80
Particle Size After Heat Sterilization (mean \pm std dev.)	81 \pm 39 nm.

25

EXAMPLE 3

In the manner of Example 1, a cyclosporin-containing emulsion was prepared without free fatty acid having the following components:

	Components	%w/w
5	Cyclosporin A	2%
	Egg phospholipid	2.5%
	Miglyol 818	15%
	Glycerol	2.5%
	Water, to make	100 g
10	pH	7.0
	Particle Size After Heat Sterilization (mean \pm std dev.)	103 \pm 34 nm

15

EXAMPLE 4

In the manner of Example 1, a cyclosporin-containing emulsion with a non-ionic surfactant and without a free fatty acid was prepared having the following components:

	Components	%w/w
20	Cyclosporin A	3%
	Egg phospholipid	2.0%
	Miglyol 810	20%
	Tween 20	1%
	Glycerol	5.0%
25	Water, to make	100 g
	pH	6.5
	Particle Size (mean \pm std dev.)	129 \pm 27 nm

EXAMPLE 5

In the manner of Example 1, a cyclosporin-containing emulsion with a non-ionic detergent was prepared having the following components:

5

	Components	%w/w
	Cyclosporin A	5%
	Egg phospholipid	1.0%
	DMPG	0.2%
10	Miglyol 810	15%
	Linoleic acid	5%
	Glycerol	2.5%
	Tween 20	0.5%
	Water, to make	100 g
15	pH	5.6
	Particle Size After Heat Sterilization (mean \pm std dev.)	318 \pm 105 nm

20

EXAMPLE 6

In the manner of Example 1, a cyclosporin-containing emulsion with natural and synthetic triglycerides were prepared having the following components:

- 25

	Components	%w/w
	Cyclosporin A	5%
	Egg phospholipid	2%
	Miglyol 810	23.75%
	Glycerol	3.75%

15

Water, to make	100 g
pH	7.0
Particle Size (mean \pm std dev.)	294 \pm 76 nm

5

WHAT IS CLAIMED IS:

- 1 1. A pharmaceutical composition consisting essentially of an oil-in-water emulsion composed of a synthetic medium chain triglyceride containing primarily C₈-C₁₂ fatty acid chains in which is dissolved a therapeutically effective amount of cyclosporin, phospholipid and an aqueous phase.
- 6 2. A pharmaceutical composition consisting essentially of an oil-in-water emulsion composed of a synthetic medium chain triglyceride containing primarily C₈-C₁₂ fatty acid chains in which is dissolved a therapeutically effective amount of cyclosporin, phospholipid, a free fatty acid or a salt thereof and an aqueous phase.
- 11 3. A pharmaceutical composition consisting essentially of an oil-in-water emulsion composed of
 - about 10% to about 40% of a synthetic medium chain triglyceride containing C₈-C₁₂ fatty acid chains;
 - about 1% to about 10% w/w of cyclosporin;
 - 16 about 1 to about 5% w/w of natural and/or synthetic phospholipid;
 - about 0.1 to about 10% w/w unsaturated free fatty acids or salts thereof; and
 - balance aqueous phase optionally also including glycerol, salts, buffers, surfactants, antioxidants, osmotic modifiers or preservatives.
- 21 4. A pharmaceutical composition consisting essentially of an oil-in-water emulsion composed of
 - about 10% to about 40% of a synthetic medium chain triglyceride containing C₈-C₁₂ fatty acid chains;
 - about 1% to about 10% w/w of cyclosporin;
 - 26 about 1 to about 5% w/w of natural or synthetic phospholipid; and
 - balance aqueous phase optionally also including glycerol, salts, buffers, surfactants, antioxidants, osmotic modifiers or preservatives.

- 1 5. The composition of claims 1, 2, 3 or 4 wherein the synthetic medium chain triglyceride has C₈-C₁₀ fatty acid chains.
- 6 6. The composition of claim 5 wherein the synthetic medium chain triglyceride consists primarily of C₈ fatty acid chains.
- 6 7. The composition of claims 1, 2, 3 or 4 wherein the phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, lysophospholipids, egg phospholipid, soy phospholipid or a mixture thereof.
- 11 8. The composition of claim 2 or 3 wherein the unsaturated free fatty acid is linoleic acid, linolenic acid or a mixture thereof.
- 16 9. The composition of claim 2, 3 or 4 wherein the composition contains from about 2.5 to about 7.5% w/w cyclosporin.
- 16 10. The composition of claim 1, 2, 3 or 4 wherein the cyclosporin is cyclosporin A.
- 21 11. The composition of claim 3 or 4 wherein the amount of phospholipid is up to about 3% w/w.
- 21 12. The composition of claim 2 or 3 wherein the amount of free fatty acid is about 1% to about 5% w/w.
- 26 13. The composition of claim 1, 2, 3 or 4 wherein the aqueous phase contains water and at least one of an antioxidant, preservative, osmotic modifier, salt, glycerol, ionic surfactant or non-ionic surfactant.

- 1 14. The composition of claim 1, 2 or 3 wherein the emulsion additionally contains natural triglycerides.
15. A method of preparing a stable emulsion of cyclosporin comprising the steps of:
- 6 (1) dissolving cyclosporin in a synthetic medium chain triglyceride to which has been added a cyclosporin solubility enhancing amount of an unsaturated free fatty acid or a salt thereof and phospholipid to produce an oil phase;
- 11 (2) preparing an aqueous phase containing water and optionally an antioxidant, preservative, osmotic modifier, salt, glycerol, ionic surfactant or non-ionic surfactant;
- (3) mixing the oil phase with the aqueous phase and subjecting the mixture to homogenizing conditions to prepare a stable cyclosporin emulsion in which substantially all of the particles have a size less than 1 μm .
- 16
16. The process of claim 15 including the additional step (4) of:
heat or filter sterilizing the stable emulsion of step (3).
- 21
17. The process of claim 15 wherein the synthetic medium chain triglyceride has C_8 - C_{10} fatty acid chains.
18. The process of claim 16 wherein the synthetic medium chain triglyceride consists primarily of C_8 fatty acid chains.
- 26
19. The process of claim 15 wherein the phospholipid is selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylglycerol, phosphatidic

- 1 acid, lysophospholipids, egg phospholipid, soy phospholipid and phosphatidyl
glycerol.
20. The process of claim 15 wherein the unsaturated free fatty acid is linoleic acid,
linolenic acid or a mixture thereof.
- 6 21. The process of claim 15 wherein the emulsion contains about 2.5 to about 7.5%
w/w cyclosporin.
22. The process of claim 15 wherein the cyclosporin is cyclosporin A.
- 11 23. The process of claim 15 wherein the amount of phospholipid is up to about 3%
w/w.
24. The process of claim 15 wherein the amount of free fatty acid or fatty acid salt
16 is about 1% to about 5% by w/w.
25. The process of claim 15 wherein the aqueous phase contains water and
optionally an antioxidant, preservative, osmotic modifier, salt, glycerol, ionic
surfactant or non-ionic surfactant.
- 21 26. The process of claims 15 wherein the cyclosporine is dissolved in a mixture of
synthetic and natural triglycerides.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97/04794

A. CLASSIFICATION OF SUBJECT MATTER A 61 K 38/13, A 61 K 9/107		
According to International Patent Classification (IPC) or to both national classification and IPC ⁶		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) A 61 K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP, A, 0 391 369 (YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNI- VERSITY OF JERUSALEM) 10 October 1990 (10.10.90), claims 1-22, 28. --	1-26
X	EP, A, 0 570 829 (DIETL) 24 November 1993 (24.11.93), claims. --	1-26
A	US, A, 4 990 337 (KOZO KURIHARA et al.) 05 February 1991 (05.02.91), claims 1-5. ----	1-6
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "A" document member of the same patent family		
Date of the actual completion of the international search 08 July 1997		Date of mailing of the international search report 18.08.97
Name and mailing address of the ISA European Patent Office, P.O. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer WOLF e.h.

ANHANG

zum internationalen Recherchen-
bericht über die internationale
Patentanmeldung Nr.

ANNEX

to the International Search
Report to the International Patent
Application No.

ANNEXE

au rapport de recherche inter-
national relatif à la demande de brevet
international n°

PCT/US 97/04794 SA 157822

In diesem Anhang sind die Mitglieder
der Patentfamilien der in obenge-
nannten internationalen Recherchenbericht
angeführten Patentdokumente angegeben.
Diese Angaben dienen nur zur Unter-
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family
members relating to the patent documents
cited in the above-mentioned inter-
national search report. The Office is
in no way liable for these particulars
which are given merely for the purpose
of information.

La présente annexe indique les
membres de la famille de brevets
relatifs aux documents de brevets cités
dans le rapport de recherche inter-
national visé ci-dessus. Les renseigne-
ments fournis sont donnés à titre indica-
tif et n'engagent pas la responsabilité
de l'Office.

Im Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A2 391369	10-10-90	AT E 110543 AU A1 52927790 AU B2 38144465 CA AA 30133785 CA CO 30133785 DE T2 69011593 DE T3 69011593 EP A3 391369 EP B1 391369 EP A0 391369 IL A1 94245000 JP A2 239080049 JP B4 71218557 KR B1 93000044 US A 53646332 IL A0 898556 IL A1 898556	15-09-94 11-10-90 39-08-91 05-10-90 05-11-93 05-10-94 12-01-95 24-04-91 31-08-94 39-11-90 27-11-90 20-11-90 29-12-90 06-01-93 15-11-94 15-12-89 13-05-93
EP A1 570829	24-11-93	JP A2 6279307 US A 3827537 DE A1 4315921	04-10-94 18-06-96 25-11-93
US A 4990337	05-02-91	JP A2 2049733 AT E 73676 AU A1 28853789 AU B2 609242 CA A1 1326695 CA CO 68900991 EP A1 327280 EP B1 327280 ES T 2033086 HK A 356797	20-02-90 15-04-92 03-08-89 26-04-91 15-02-94 23-04-92 09-08-89 18-03-93 01-03-96 27-03-97